U.S. FDA approval of INLEXZO™ (gemcitabine intravesical system) set to transform how certain bladder cancers are treated
1. JNJ's INLEXZO™ received FDA approval for bladder cancer treatment. 2. 82% of patients achieved complete response without reinduction. 3. Offers alternative for BCG-unresponsive patients facing surgery. 4. First drug system for extended local delivery into the bladder. 5. Well-tolerated with clinically meaningful results; high durability noted.